PD-L1 expression and its effect on clinical outcomes of EGFRmutant NSCLC patients treated with EGFR-TKIs

Yuchen Bai; Xiaoxia Chen; Likun Hou; Jun Qian; Tao Jiang; Caicun Zhou; Maciej Ciebiada

首页> 中文期刊> 《癌症生物学与医学：英文版》 >PD-L1 expression and its effect on clinical outcomes of EGFRmutant NSCLC patients treated with EGFR-TKIs

PD-L1 expression and its effect on clinical outcomes of EGFRmutant NSCLC patients treated with EGFR-TKIs

开具论文收录证明 >>

期刊封面封底目录下载 >>

文献代查 >>

页面导航

摘要
著录项
相关主题

摘要

Objective: Epidermal growth factor receptor (EGFR) activation was reported to upregulate programmed death-ligand 1 (PD-L1) expression in lung cancer cells and subsequently contribute to immune escape, indicating its critical role in EGFR-driven lung tumors. This study characterized PD-L1 expression in patients with surgically resected EGFR-mutant non-small cell lung cancer (NSCLC). The effect of PD-L1 expression on clinical outcomes was also investigated in advanced EGFR-mutant NSCLC treated with EGFR-tyrosine kinase inhibitors (TKIs).Methods: In total, 73 patients with surgically resected NSCLC and EGFR mutations were identified. PD-L1 expression and CD8+tumor-infiltrating lymphocyte (TIL) density were assessed by immunohistochemistry. A literature review of publications that assessed the predictive and prognostic value of PD-L1 expression in advanced EGFR-mutant NSCLC patients treated with EGFRTKIswas performed.Results: Nineteen (26.0%) patients were positive for PD-L1 expression, which was significantly associated with concomitant KRAS mutation (P = 0.020) and marginally associated with higher CD8+ TILs density (P = 0.056). Positive PD-L1 expression was associated with markedly inferior overall survival (OS) in multivariate analysis (P = 0.032). The combination of PD-L1 and CD8+TILs expression could be used to stratify the population into three groups with distinct prognoses. A meta-analysis of sixpublications showed that positive PD-L1 expression was not associated with OS [hazard ratio (HR) = 0.90; 95% confidence interval (CI), 0.42–1.38] or progression-free survival (HR = 1.03; 95 CI, 0.73–1.33) in advanced EGFR-mutant NSCLC patients receiving EGFR-TKIs.Conclusions: PD-L1 expression tended to correlate with CD8+ TIL expression, concomitant KRAS mutation, and poor survival in surgically resected EGFR-mutant NSCLC. PD-L1 expression was neither the predictive nor the prognostic factor in advanced EGFR-mutant NSCLC patients treated with EGFR-TKIs.

著录项

来源
《癌症生物学与医学：英文版》 |2018年第4期|P.434-442|共9页
作者
Yuchen Bai; Xiaoxia Chen; Likun Hou; Jun Qian; Tao Jiang; Caicun Zhou; Maciej Ciebiada;
展开▼
作者单位

[1]Department of General and Oncological Pulmonology;

University Clinical Hospital Norbert Barlicki;

Medical University of Lodz;

Lodz 50243;

Poland;

[2]Department of Urology;

Shanghai General Hospital;

Shanghai Jiao Tong University School of Medicine;

Shanghai 200011;

China;

[3]Department of Medical Oncology;

[4]Department of Pathology;

Shanghai Pulmonary Hospital & Thoracic Cancer Institute;

Tongji University School of Medicine;

Shanghai 200433;

China;

[5]Department of Medical Oncology;

Suzhou Cancer Center;

the Affiliated Suzhou Hospital of Nanjing Medical University;

Suzhou 215000;

China;

[3]Department of Medical Oncology;

[3]Department of Medical Oncology;

[1]Department of General and Oncological Pulmonology;

University Clinical Hospital Norbert Barlicki;

Medical University of Lodz;

Lodz 50243;

Poland;

展开▼
原文格式 PDF
正文语种 CHI
中图分类医药、卫生;
关键词
Non-small cell lung cancer; EGFR mutation; PD-L1; CD8; survival;

机译：非小细胞肺癌;EGFR突变;PD-L1;CD8;生存;

PD-L1 expression and its effect on clinical outcomes of EGFRmutant NSCLC patients treated with EGFR-TKIs

摘要

著录项

相关主题

期刊订阅